104 related articles for article (PubMed ID: 30763062)
1. GLI1-Inducible Glucuronidation Targets a Broad Spectrum of Drugs.
Zahreddine HA; Culjkovic-Kraljacic B; Gasiorek J; Duchaine J; Borden KLB
ACS Chem Biol; 2019 Mar; 14(3):348-355. PubMed ID: 30763062
[TBL] [Abstract][Full Text] [Related]
2. The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation.
Zahreddine HA; Culjkovic-Kraljacic B; Assouline S; Gendron P; Romeo AA; Morris SJ; Cormack G; Jaquith JB; Cerchietti L; Cocolakis E; Amri A; Bergeron J; Leber B; Becker MW; Pei S; Jordan CT; Miller WH; Borden KL
Nature; 2014 Jul; 511(7507):90-3. PubMed ID: 24870236
[TBL] [Abstract][Full Text] [Related]
3. Molecular targeting of the UDP-glucuronosyltransferase enzymes in high-eukaryotic translation initiation factor 4E refractory/relapsed acute myeloid leukemia patients: a randomized phase II trial of vismodegib, ribavirin with or without decitabine.
Assouline S; Gasiorek J; Bergeron J; Lambert C; Culjkovic-Kraljacic B; Cocolakis E; Zakaria C; Szlachtycz D; Yee K; Borden KLB
Haematologica; 2023 Nov; 108(11):2946-2958. PubMed ID: 36951168
[TBL] [Abstract][Full Text] [Related]
4. Molecular Pathways: GLI1-Induced Drug Glucuronidation in Resistant Cancer Cells.
Zahreddine HA; Borden KL
Clin Cancer Res; 2015 May; 21(10):2207-10. PubMed ID: 25810373
[TBL] [Abstract][Full Text] [Related]
5. When will resistance be futile?
Borden KL
Cancer Res; 2014 Dec; 74(24):7175-80. PubMed ID: 25477336
[TBL] [Abstract][Full Text] [Related]
6. Inducible drug modification: a new form of resistance.
Culjkovic-Kraljacic B; Zahreddine HA; Borden KL
Cell Cycle; 2014; 13(16):2485-6. PubMed ID: 25486186
[No Abstract] [Full Text] [Related]
7. Potential role of Shh-Gli1-BMI1 signaling pathway nexus in glioma chemoresistance.
Shahi MH; Farheen S; Mariyath MP; Castresana JS
Tumour Biol; 2016 Nov; 37(11):15107-15114. PubMed ID: 27662839
[TBL] [Abstract][Full Text] [Related]
8. A genome scale RNAi screen identifies GLI1 as a novel gene regulating vorinostat sensitivity.
Falkenberg KJ; Newbold A; Gould CM; Luu J; Trapani JA; Matthews GM; Simpson KJ; Johnstone RW
Cell Death Differ; 2016 Jul; 23(7):1209-18. PubMed ID: 26868908
[TBL] [Abstract][Full Text] [Related]
9. Overcoming Drug Resistance through the Development of Selective Inhibitors of UDP-Glucuronosyltransferase Enzymes.
Osborne MJ; Coutinho de Oliveira L; Volpon L; Zahreddine HA; Borden KLB
J Mol Biol; 2019 Jan; 431(2):258-272. PubMed ID: 30428301
[TBL] [Abstract][Full Text] [Related]
10. Gli1 is a potential target for alleviating multidrug resistance of gliomas.
Cui D; Xu Q; Wang K; Che X
J Neurol Sci; 2010 Jan; 288(1-2):156-66. PubMed ID: 19818966
[TBL] [Abstract][Full Text] [Related]
11. Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein.
Stam RW; van den Heuvel-Eibrink MM; den Boer ML; Ebus ME; Janka-Schaub GE; Allen JD; Pieters R
Leukemia; 2004 Jan; 18(1):78-83. PubMed ID: 14574327
[TBL] [Abstract][Full Text] [Related]
12. Sonic Hedgehog factor Gli1: As good as resistant.
Zahreddine HA; Culjkovic-Kraljacic B; Borden KL
Mol Cell Oncol; 2015; 2(1):e961827. PubMed ID: 27308395
[TBL] [Abstract][Full Text] [Related]
13. GLI inhibitors overcome Erlotinib resistance in human pancreatic cancer cells by modulating E-cadherin.
Ghanbari A; Cheraghzadeh Z; Mahmoudi R; Zibara K; Hosseini E
J Chemother; 2019 May; 31(3):141-149. PubMed ID: 30983542
[TBL] [Abstract][Full Text] [Related]
14. Targeting GLI1 Suppresses Cell Growth and Enhances Chemosensitivity in CD34+ Enriched Acute Myeloid Leukemia Progenitor Cells.
Long B; Wang LX; Zheng FM; Lai SP; Xu DR; Hu Y; Lin DJ; Zhang XZ; Dong L; Long ZJ; Tong XZ; Liu Q
Cell Physiol Biochem; 2016; 38(4):1288-302. PubMed ID: 27008269
[TBL] [Abstract][Full Text] [Related]
15. Aspirin inhibits the SHH/GLI1 signaling pathway and sensitizes malignant glioma cells to temozolomide therapy.
Ming J; Sun B; Li Z; Lin L; Meng X; Han B; Wang R; Wu P; Li J; Cai J; Jiang C
Aging (Albany NY); 2017 Apr; 9(4):1233-1247. PubMed ID: 28446712
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status.
Minderman H; Zhou Y; O'Loughlin KL; Baer MR
Cancer Chemother Pharmacol; 2007 Jul; 60(2):245-55. PubMed ID: 17096161
[TBL] [Abstract][Full Text] [Related]
17. GLI1 Blockade Potentiates the Antitumor Activity of PI3K Antagonists in Lung Squamous Cell Carcinoma.
Kasiri S; Shao C; Chen B; Wilson AN; Yenerall P; Timmons BC; Girard L; Tian H; Behrens C; Wistuba II; Gazdar AF; Kim J
Cancer Res; 2017 Aug; 77(16):4448-4459. PubMed ID: 28652248
[TBL] [Abstract][Full Text] [Related]
18. GLI1-mediated regulation of side population is responsible for drug resistance in gastric cancer.
Yu B; Gu D; Zhang X; Li J; Liu B; Xie J
Oncotarget; 2017 Apr; 8(16):27412-27427. PubMed ID: 28404967
[TBL] [Abstract][Full Text] [Related]
19. MiR-873 inhibition enhances gefitinib resistance in non-small cell lung cancer cells by targeting glioma-associated oncogene homolog 1.
Jin S; He J; Li J; Guo R; Shu Y; Liu P
Thorac Cancer; 2018 Oct; 9(10):1262-1270. PubMed ID: 30126075
[TBL] [Abstract][Full Text] [Related]
20. miR-132 weakens proliferation and invasion of glioma cells via the inhibition of Gli1.
Wang YZ; Han JJ; Fan SQ; Yang W; Zhang YB; Xu TJ; Xu GM
Eur Rev Med Pharmacol Sci; 2018 Apr; 22(7):1971-1978. PubMed ID: 29687851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
